Cilastatin

Cystic Fibrosis

Hartford HospitalSmall moleculePhase 4 / ApprovedActive

B

56/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 44/ 100
Competitive Position: 73/ 100

Competitive context

80 Active assets in the Cystic Fibrosis cohort.

Asset / Sponsor	Phase	Rating
Tezacaftor Vertex Pharmaceuticals Incorporated	Phase 4	A
Lumacaftor Hospices Civils de Lyon	Phase 4	BBB
Ivacaftor Meyer Children's Hospital IRCCS	Phase 4	BBB
Liprotamase Anthera Pharmaceuticals	Phase 4	BBB
Elexacaftor Meyer Children's Hospital IRCCS	Phase 4	BBB

View all 50 →

Same molecule, other indications

Cilastatin is also rated in:

bacterial pneumoniaActive

B

Indicative · Phase 4

59 / 100

hematopoietic and lymphoid cell neoplasmActive

CCC

Indicative · Phase 2

54 / 100

cancerActive

CCC

Indicative · Phase 2

54 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.